Novonesis invests 600 million euros in India enzyme plant
Analysis based on 12 articles · First reported Sep 02, 2026 · Last updated Sep 03, 2026
The investment signals Novonesis's confidence in long-term demand for biosolutions and its commitment to expanding capacity in high-growth emerging markets, which could support revenue growth and market share. The announcement, coupled with raised guidance and capital returns, is likely to be viewed positively by investors, potentially supporting the company's share price.
On September 2, 2026, Novonesis announced a €600 million investment to expand its enzyme production facility in Patalganga, India, and build one of the world's most advanced enzyme production plants. The facility, expected to be fully operational by 2030, will produce enzymes for biofuels, household care, and food and beverages. The investment aims to increase production capacity to meet rising global demand for biosolutions and strengthen supply chain resilience. It is part of a series of global capacity expansions, including sites in Thailand, the United States, China, and Brazil. The new plant will incorporate water recycling and heat pumps to reduce emissions. Novonesis executives, including CEO Ester Baiget and COO Anders Lund, emphasized the strategic importance of the expansion and its role in serving fast-growing markets in the Middle East, India, and Africa. The announcement follows the company's half-year 2026 results, which showed organic sales growth of 8% and an adjusted EBITDA margin of 37.7%, and it raised its full-year outlook. The company also recently approved a dividend and a €1 billion share buyback, and signed an agreement to acquire the remaining 77% of MicroBioGen.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard